Focusing on the suppression of type 2 immune responses, several biologics targeting IL-4 and/or IL-13 and oral Janus kinase (JAK) inhibitors have been developed and shown in clinical trials to be effective and safe in moderate-to-severe AD [4,5,6,7,8,9]. The gene discussed is IL13; the disease is Alzheimer disease.